Creating Innovative New Drugs to Address Patients’ Unmet Medical Needs
First written in FY2016. 19 of 21 entries say "Restated". Latest entry: 2026-05-21.
2 other companies' latest entry also says "Restated".
- 2026-05-21RestatedGeneral Meetings of Shareholders
「Guided by our corporate philosophy, “For the human fight against disease and suffering,” we are concentrating management resources on the discovery and development of new drugs and developing the human resources that will support future growth, with the aim of becoming a global specialty pharmaceutical company that continues to provide original and innovative medicines to patients worldwide.」
The corporate philosophy, the goal of becoming a global specialty pharmaceutical company, and the concentration of management resources on new drug discovery and development were reaffirmed. - FY2024RestatedAnnual report
「Under the corporate philosophy “For the human fight against disease and suffering,” our group continues to make active efforts to become a “global specialty pharmaceutical company” that creates innovative new drugs that truly benefit patients and address unmet medical needs.」
The core policy of creating innovative new drugs to address unmet medical needs and becoming a global specialty pharmaceutical company is reaffirmed. - FY2024-Q1RestatedAnnual report
「Under the corporate philosophy “For the human fight against disease and suffering,” our group conducts its business by concentrating its management resources on the single Pharmaceuticals segment, covering research and development, procurement, manufacturing and sales, with the aim of creating innovative new drugs that truly benefit patients and address unmet medical needs.」
The corporate philosophy, the objective of creating innovative new drugs to address unmet medical needs, and the concentration of management resources on the Pharmaceuticals business are reaffirmed. - FY2023RestatedAnnual report
「Under the corporate philosophy “For the human fight against disease and suffering,” our group continues to make active efforts to become a “global specialty pharmaceutical company” that creates innovative new drugs that truly benefit patients and address unmet medical needs.」
The core policy of creating innovative new drugs to address patients’ unmet medical needs and becoming a global specialty pharmaceutical company is reaffirmed. - FY2023-Q3RestatedAnnual report
「Under the corporate philosophy “For the human fight against disease and suffering,” our group conducts its business by concentrating its management resources on the single Pharmaceuticals segment, covering research and development, procurement, manufacturing and sales, with the aim of creating innovative new drugs that truly benefit patients and address unmet medical needs. Accordingly, information by reportable segment is omitted.」
The corporate philosophy, the objective of creating innovative new drugs to address unmet medical needs, and the concentration of management resources on the Pharmaceuticals business are reaffirmed. - FY2023-Q2RestatedAnnual report
「Under the corporate philosophy “For the human fight against disease and suffering,” our group continues to take on disease areas where diseases remain unconquered or where patient treatment satisfaction remains low and medical needs are high, while steadily working to create original and groundbreaking pharmaceuticals.」
The core objective of taking on disease areas with high unmet medical needs and creating original, groundbreaking pharmaceuticals under the corporate philosophy is reaffirmed. - FY2022RestatedAnnual report
「Under the corporate philosophy “For the human fight against disease and suffering,” our group continues to make active efforts to become a “global specialty pharmaceutical company” that creates innovative new drugs that truly benefit patients and address unmet medical needs.」
The core policy of creating innovative new drugs to address unmet medical needs and becoming a global specialty pharmaceutical company is reaffirmed. - FY2022-Q3RestatedAnnual report
「Under the corporate philosophy “For the human fight against disease and suffering,” our group conducts its business by concentrating its management resources on the single Pharmaceuticals segment, covering research and development, procurement, manufacturing and sales, with the aim of creating innovative new drugs that truly benefit patients and address unmet medical needs.」
The policy of creating innovative new drugs to address unmet medical needs under the corporate philosophy is reaffirmed together with the concentration of management resources on a single segment. - FY2022-Q1RestatedAnnual report
「Under the corporate philosophy “For the human fight against disease and suffering,” our group conducts its business by concentrating its management resources on the single Pharmaceuticals segment, covering research and development, procurement, manufacturing and sales, with the aim of creating innovative new drugs that truly benefit patients and address unmet medical needs.」
The policy of creating innovative new drugs to address unmet medical needs under the corporate philosophy is reaffirmed together with the concentration of management resources on the Pharmaceuticals business. - FY2021-Q1RestatedAnnual report
「Under the corporate philosophy “For the human fight against disease and suffering,” our group conducts its business by concentrating its management resources on the single Pharmaceuticals segment, covering research and development, procurement, manufacturing and sales, with the aim of creating innovative new drugs that truly benefit patients and address unmet medical needs.」
The creation of innovative new drugs to address unmet medical needs and the concentration of management resources on the Pharmaceuticals business are reiterated in the quarterly segment information under the corporate philosophy. - FY2020ReframedAnnual report
「Under the corporate philosophy “For the human fight against disease and suffering,” our group continues to make active efforts to become a “global specialty pharmaceutical company” that creates innovative new drugs that truly benefit patients and address unmet medical needs.」
The previous objective of creating innovative new drugs to address patients’ unmet medical needs has been redefined to explicitly include the corporate vision of becoming a “global specialty pharmaceutical company.” - FY2020-Q1RestatedAnnual report
「Under the corporate philosophy “For the human fight against disease and suffering,” our group conducts its business by concentrating its management resources on the single Pharmaceuticals segment, covering research and development, procurement, manufacturing and sales, with the aim of creating innovative new drugs that truly benefit patients and address unmet medical needs.」
The corporate philosophy, the objective of creating innovative new drugs to address unmet medical needs, and the concentration of management resources on the Pharmaceuticals business are reaffirmed. - FY2019-Q3RestatedAnnual report
「Under the corporate philosophy “For the human fight against disease and suffering,” our group conducts its business by concentrating its management resources on the single Pharmaceuticals segment, covering research and development, procurement, manufacturing and sales, with the aim of creating innovative new drugs that truly benefit patients and address unmet medical needs.」
The policy of creating innovative new drugs to address unmet medical needs based on the corporate philosophy is reaffirmed together with the concentration of management resources on a single segment. - FY2018RestatedAnnual report
「Under the corporate philosophy “For the human fight against disease and suffering,” our group continues to make active efforts to create innovative new drugs that truly benefit patients and address unmet medical needs.」
The core objective of creating innovative new drugs to address unmet medical needs based on the corporate philosophy is reaffirmed. - FY2018-Q3RestatedAnnual report
「Under the corporate philosophy “For the human fight against disease and suffering,” our group conducts its business by concentrating its management resources on the single Pharmaceuticals segment, covering research and development, procurement, manufacturing and sales, with the aim of creating innovative new drugs that truly benefit patients and address unmet medical needs.」
The core objective of creating innovative new drugs to address unmet medical needs under the corporate philosophy is reiterated in the segment information. - FY2018-Q2RestatedAnnual report
「Under the corporate philosophy “For the human fight against disease and suffering,” our group continues to take on disease areas where diseases remain unconquered or where patient treatment satisfaction remains low and medical needs are high, while steadily working to create original and groundbreaking pharmaceuticals.」
The policy of taking on disease areas with high unmet medical needs and aiming to create original, groundbreaking pharmaceuticals under the corporate philosophy is reaffirmed. - FY2018-Q1RestatedAnnual report
「Under the corporate philosophy “For the human fight against disease and suffering,” our group conducts its business by concentrating its management resources on the single Pharmaceuticals segment, covering research and development, procurement, manufacturing and sales, with the aim of creating innovative new drugs that truly benefit patients and address unmet medical needs.」
The corporate philosophy, the objective of creating innovative new drugs to address unmet medical needs, and the concentration of management resources on the Pharmaceuticals business are reiterated. - FY2017RestatedAnnual report
「Under the corporate philosophy “For the human fight against disease and suffering,” our group continues to make active efforts to create innovative new drugs that truly benefit patients and address unmet medical needs.」
The core policy of creating innovative new drugs to address unmet medical needs under the corporate philosophy is reaffirmed in the annual report. - FY2017-Q2RestatedAnnual report
「Under the corporate philosophy “For the human fight against disease and suffering,” our group continues to take on disease areas where diseases remain unconquered or where patient treatment satisfaction remains low and medical needs are high, while steadily working to create original and groundbreaking pharmaceuticals.」
The objective of taking on disease areas with high unmet medical needs and creating original, groundbreaking pharmaceuticals under the corporate philosophy is reaffirmed. - FY2017-Q1RestatedAnnual report
「Under the corporate philosophy “For the human fight against disease and suffering,” our group concentrates its management resources on the single Pharmaceuticals segment, covering research and development, procurement, manufacturing and sales, with the aim of creating innovative new drugs that truly benefit patients and address unmet medical needs.」
The objective of creating innovative new drugs to address unmet medical needs, based on the corporate philosophy, is reiterated in the quarterly segment information. - FY2016First statedAnnual report
「Under the corporate philosophy “For the human fight against disease and suffering,” we continue to make active efforts to create innovative new drugs that truly benefit patients and address unmet medical needs.」
This is the first appearance of a core objective linking the corporate philosophy with the creation of innovative new drugs for patients.